Navigation Links
Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
Date:5/20/2008

LOS ANGELES, May 20 /PRNewswire/ -- Vista Partners announced today that it has initiated coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE). Ross Silver, Director of Research of Vista Partners stated, "Alseres' recombinant-protein-based drug named Cethrin has shown highly encouraging clinical and preclinical data to date. Cethrin would serve a multi-billion dollar market if approved. In addition to Cethrin, Alseres has a molecular imaging program in Phase III clinical trials, a program we believe will likely be partnered within the next 12 months. Alseres is a highly attractive investment at its current valuation." To download a free copy of the report, please visit the Vista Partners website, http://www.vistap.com and click on the download research icon.

About Vista Partners:

Vista Partners provides independent, equity research to institutional and individual investors, with a focus on publicly traded small capitalization companies. With offices in Los Angeles and San Francisco, Vista Partners is one of the fastest growing independently owned equity research firms. Vista Partners professional staff has backgrounds in finance, corporate communications and investment banking. More information is available at http://www.vistap.com.

About Alseres Pharmaceuticals, Inc.:

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact:

Vista Partners LLC

Ross Silver

(415) 738-6229

info@vistap.com

http://www.vistap.com


'/>"/>
SOURCE Vista Partners
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
2. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
3. Synvista Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp.
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Avista Capital Partners Completes Acquisition of Bristol-Myers Squibb Medical Imaging
7. Accipiter Capital Management Opposes Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
8. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
9. Boston Scientific Completes Sale of Fluid Management and Venous Access Businesses to Avista Capital Partners
10. Synvista Therapeutics to Present at the Roth 20th Annual OC Growth Stock Conference
11. Avista Capital Partners Enhances Energy Practice With Appointment of Gerhard Kurz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... February 06, 2016 , ... ... 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT: ... world with an estimated 5000 perioperative nurses in attendance to study the ...
(Date:2/5/2016)... ... ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the Miami Marathon on January ... year, he ran all 26.2 miles with a green 25-pound ShelterBox strapped to his ... This Sunday, while many are watching the Superbowl, Steven Tonkinson will strap on the ...
(Date:2/5/2016)... , ... February 05, 2016 , ... The event is ... Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 ... owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this ...
(Date:2/5/2016)... Toronto, Ontario (PRWEB) , ... February 05, 2016 , ... ... the Scarborough General Hospital Burn Unit, plastic and cosmetic surgeon Dr. Wayne Carman transitioned ... the Scarborough Hospital. He successfully completed his first three-year term as chief and began ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know the routine: each January, ... to access the treadmills. It’s a predictable trend. After the excesses of November and ... in shape by joining gyms, starting new walking or running routines, or signing up ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... -- The Senior Care Pharmacy Coalition (SCPC) today commended ... Jason Chaffetz (R-UT) and Ranking Member Elijah ... "Developments in the Prescription Drug Market," to examine ... abusive pharmacy benefit manager (PBM) pricing practices. ... Elijah Cummings (D-MD) are diligent, serious lawmakers committed ...
(Date:2/4/2016)... , Feb. 4, 2016   Bernstein Liebhard LLP ... filed in the United States District Court for the District ... class (the "Class") consisting of all persons or entities who ... "Company") (NASDAQ: INSY ) from March 3, 2015 through ... and certain of its officers with violations of the Securities ...
(Date:2/4/2016)... 2016 Wegener Polyangiitis - Pipeline Review, ... ,Wegener Polyangiitis - Pipeline Review, H2 2015, provides ... This report provides comprehensive information on the ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
Breaking Medicine Technology: